• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿曼的川崎病——一项临床研究。

Kawasaki disease in Oman--a clinical study.

作者信息

Bhatnagar Sunil Kumar, Paul George, Subramanian Raghavan, Al Hosni Mohammad S, Al Khusaiby Saleh Mohamed

机构信息

Paediatric Infectious Diseases Unit, Division of Child Health, The Royal Hospital, Ministry of Health, Sultanate of Oman.

出版信息

J Trop Pediatr. 2003 Dec;49(6):361-6. doi: 10.1093/tropej/49.6.361.

DOI:10.1093/tropej/49.6.361
PMID:14725413
Abstract

A total of 39 patients were diagnosed to have Kawasaki disease by the standard diagnostic criteria, at The Royal Hospital, Muscat, Oman, during the period January 1995 to August 2002. A retrospective analysis of the case records of the patients with the diagnosis of Kawasaki disease was done. The results of the clinical features and the laboratory manifestations of the patients, who are from the Middle East region, are presented. The peak age at presentation was 6-30 months, mean 29 months. Peak months of the occurrence of the disease were March and October. Oral lesions were found in all cases. The mean duration of hospital stay for these patients was 8.5 days, range 2-21 days. The total duration of fever ranged from 6 to 21 days, with a mean value of 9.4 days. An elevated erythrocytic sedimentation rate (ESR; 91.7 per cent) and a raised C-reactive protein (C-RP; 92.3 per cent) were the most significant laboratory findings. Echocardiographic abnormalities were found in 25 per cent of cases, the incidence of coronary artery involvement (dilatation with or without stenosis) being 12.5 per cent. High dose intravenous immunoglobulin (2 g/kg over a 12-h period) plus aspirin therapy was found to be safe and effective in patients with Kawasaki disease.

摘要

1995年1月至2002年8月期间,阿曼马斯喀特皇家医院共有39例患者根据标准诊断标准被诊断为川崎病。对诊断为川崎病的患者病历进行了回顾性分析。呈现了来自中东地区患者的临床特征和实验室检查结果。发病的高峰年龄为6 - 30个月,平均29个月。发病的高峰月份为3月和10月。所有病例均发现口腔病变。这些患者的平均住院时间为8.5天,范围为2 - 21天。发热总时长为6至21天,平均值为9.4天。红细胞沉降率升高(ESR;91.7%)和C反应蛋白升高(C-RP;92.3%)是最显著的实验室检查结果。25%的病例发现有超声心动图异常,冠状动脉受累(扩张伴或不伴狭窄)的发生率为12.5%。发现大剂量静脉注射免疫球蛋白(12小时内2 g/kg)加阿司匹林治疗对川崎病患者安全有效。

相似文献

1
Kawasaki disease in Oman--a clinical study.阿曼的川崎病——一项临床研究。
J Trop Pediatr. 2003 Dec;49(6):361-6. doi: 10.1093/tropej/49.6.361.
2
School-aged children with Kawasaki disease: high incidence of cervical lymphadenopathy and coronary artery involvement.患有川崎病的学龄儿童:颈部淋巴结病和冠状动脉受累的高发病率。
J Paediatr Child Health. 2003 Jan-Feb;39(1):55-7. doi: 10.1046/j.1440-1754.2003.00085.x.
3
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.英夫利昔单抗强化川崎病一线治疗:一项 3 期随机、双盲、安慰剂对照试验。
Lancet. 2014 May 17;383(9930):1731-8. doi: 10.1016/S0140-6736(13)62298-9. Epub 2014 Feb 24.
4
Predictive risk factors for coronary artery abnormalities in Kawasaki disease.川崎病冠状动脉异常的预测风险因素。
Eur J Pediatr. 2007 May;166(5):421-5. doi: 10.1007/s00431-006-0251-8. Epub 2006 Oct 11.
5
Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.免疫球蛋白联合泼尼松龙预防重症川崎病冠状动脉异常的疗效(RAISE 研究):一项随机、开放标签、盲终点试验。
Lancet. 2012 Apr 28;379(9826):1613-20. doi: 10.1016/S0140-6736(11)61930-2. Epub 2012 Mar 8.
6
Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.大剂量与小剂量阿司匹林联合静脉注射免疫球蛋白治疗川崎病的比较。
Clin Pediatr (Phila). 2002 Oct;41(8):597-601. doi: 10.1177/000992280204100807.
7
Erythrocyte sedimentation rate and C-reactive protein discrepancy and high prevalence of coronary artery abnormalities in Kawasaki disease.川崎病中红细胞沉降率与C反应蛋白的差异及冠状动脉异常的高患病率
Pediatr Infect Dis J. 2001 Jul;20(7):698-702. doi: 10.1097/00006454-200107000-00011.
8
Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.用中等剂量(1克/千克)静脉注射免疫球蛋白治疗川崎病。
J Med Assoc Thai. 2002 Nov;85 Suppl 4:S1121-6.
9
Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.纤溶酶处理的静脉注射丙种球蛋白治疗川崎病的疗效。
Pediatr Infect Dis J. 1993 Jun;12(6):509-12. doi: 10.1097/00006454-199306000-00010.
10
Clinical characteristics of Kawasaki syndrome and the risk factors for coronary artery lesions in China.中国川崎病的临床特征及冠状动脉病变的危险因素。
Pediatr Infect Dis J. 2013 Oct;32(10):e397-402. doi: 10.1097/INF.0b013e31829dd45e.

引用本文的文献

1
Early Diagnosis and Cardiac Complications of Kawasaki Disease in a Resource-Limited Regional Hospital.资源有限地区医院中川崎病的早期诊断及心脏并发症
Cureus. 2025 Apr 13;17(4):e82205. doi: 10.7759/cureus.82205. eCollection 2025 Apr.
2
Atypical Kawasaki Disease in a 16-Month-Old Baby: A Case Report and Literature Review.一名16个月大婴儿的非典型川崎病:病例报告及文献综述
Cureus. 2023 May 22;15(5):e39336. doi: 10.7759/cureus.39336. eCollection 2023 May.
3
The Most Common Clinical Features of Kawasaki Disease Patients in King Abdulaziz Medical City.
阿卜杜勒阿齐兹国王医疗城川崎病患者的最常见临床特征
Cureus. 2021 May 19;13(5):e15127. doi: 10.7759/cureus.15127.
4
Kawasaki disease: Clinico-laboratory spectrum and outcome in a cohort of children treated at a tertiary care hospital in Islamabad, Pakistan.川崎病:在巴基斯坦伊斯兰堡一家三级医疗医院接受治疗的一组儿童的临床实验室特征及预后
Pak J Med Sci. 2020 Jan-Feb;36(2):260-264. doi: 10.12669/pjms.36.2.910.
5
Clinical and epidemiological characteristics of kawasaki disease.川崎病的临床与流行病学特征
Jundishapur J Microbiol. 2014 Aug;7(8):e11014. doi: 10.5812/jjm.11014. Epub 2014 Jul 27.
6
Recurrent lip swelling as a late presentation of Kawasaki disease: Case report and review of literature.复发性唇部肿胀作为川崎病的晚期表现:病例报告及文献复习
Saudi Dent J. 2013 Jan;25(1):43-7. doi: 10.1016/j.sdentj.2012.10.001. Epub 2012 Oct 27.
7
Cardiac involvement in Kawasaki disease in Pakistani children.巴基斯坦儿童川崎病的心脏受累情况。
Ann Pediatr Cardiol. 2012 Jul;5(2):129-32. doi: 10.4103/0974-2069.99612.